IceCure Medical Ltd (ICCM) U.S. Food And Drug Administration's Marketing Authorization For ProSense Cryoablation Call Transcript
Source: SeekingAlpha
2025-10-06 11:52:51 ET
IceCure Medical Ltd (ICCM) U.S. Food and Drug Administration's Marketing Authorization for ProSense Cryoablation Call...
Read the full article on Seeking Alpha
For further details see:
IceCure Medical Ltd (ICCM) U.S. Food And Drug Administration's Marketing Authorization For ProSense Cryoablation Call Transcript
IceCure Medical Ltd.
NASDAQ: ICCM
ICCM Trading
4.6% G/L:
$0.687 Last:
157,741 Volume:
$0.6598 Open:
ICCM Latest News
March 11, 2026 08:30:00 am
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer
March 10, 2026 08:30:00 am
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
ICCM Stock Data
$41,357,048
35,998,493
N/A
10
N/A
Medical Equipment & Supplies
Healthcare
IL
Caesarea
